共刺激分子CD40／CD40L靶向治疗的策略及应用进展

Strategy and clinical translational advances of targeting the costimulatory molecule CD40/CD40L for neoplasm therapy

共刺激分子CD40广泛表达于免疫细胞、造血干细胞、内皮细胞及多种肿瘤细胞。作为新的肿瘤治疗靶细胞，CD40／CD40L可以通过免疫活化的间接作用和对肿瘤细胞毒性的直接作用来介导肿瘤的衰退。针对CD40／CD40L通路的药物已在进展期肿瘤患者中进行了临床I期试验和评价，初步结果显示出了客观的临床效应和免疫调节作用，并且没有严重的不良反应。

Costimulatory molecule CD40 is extensively expressed by immune, hematopoietic, epithelial, and a wide range of tumor cells. As a potential target for novel cancer therapy, CD40/CD40L may mediate tumor regression through both an indirect effect of immune activation and a direct cytotoxic effect on the tumor. Several drug formulations that target the CD40/CD40L pathway have undergone phase I clinical evaluation in advanced-stage cancer patients, and initial findings show objective clinical responses immune modulation funetion and have not serious toxicity.